Brief psychodynamic interpersonal psychotherapy for patients with multisomatoform disorder: Randomised controlled trial

British Journal of Psychiatry

Volumn 200, Issue 1, 2012, Pages 60-67

  Sattel, H ^a   Lahmann, C ^a,b   Gundel, H ^c   Guthrie, E ^d   Kruse, J ^e,f   Noll Hussong, M ^c   Ohmann, C ^e   Ronel, J ^a   Sack, M ^a   Sauer, N ^g,h   Schneider, G ⁱ   Henningsen, Peter ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f JUSTUS LIEBIG UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h Department of Psychosomatic Medicine   (Germany)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTISOMATOFORM DISORDER; OUTCOME ASSESSMENT; PSYCHODYNAMIC INTERPERSONAL THERAPY; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOMATOFORM DISORDER; THERAPY EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANXIETY; ATTITUDE TO HEALTH; DEPRESSIVE DISORDER, MAJOR; GERMANY; HUMANS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PAIN; PAIN MANAGEMENT; PRIMARY HEALTH CARE; PSYCHOTHERAPY, BRIEF; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SOMATOFORM DISORDERS; YOUNG ADULT;

EID: 84855529633     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.111.093526     Document Type: Article

References (40)

1. Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch Gen Psychiatry 2005; 62: 903-10. (Pubitemid 41126885)
2. Henningsen P, Zipfel S, Herzog W. Management of functional somatic syndromes. Lancet 2007; 369: 946-55. (Pubitemid 46400832)
3. Kroenke K, Sharpe M, Sykes R. Revising the classification of somatoform disorders: key questions and preliminary recommendations. Psychosomatics 2007; 48: 277-85. (Pubitemid 47001259)
4. Creed F, Fink P, Guthrie E, Henningsen P, Rief W, Sharpe M, et al. Is there a better term than 'medically unexplained symptoms'? J Psychosom Res 2010; 68: 5-8.
5. American Psychiatric Association. Somatoform Disorders - American Psychiatric Association DSM-5 Development. APA, 2010 (http://www.dsm5.org/ ProposedRevisions/Pages/SomatoformDisorders.aspx).
6. Fink P, Schröder A. One single diagnosis, bodily distress syndrome, succeeded to capture 10 diagnostic categories of functional somatic syndrome and somatoform disorders. J Psychosom Res 2010; 68: 415-25.
7. Kroenke K. Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity and management. Int J Methods Psychiatr Res 2003; 12: 34-43. (Pubitemid 36675446)
8. Kroenke K, Swindle R. Cognitive-behavioral therapy for somatization and symptom syndromes: a critical review of controlled clinical trials. Psychother Psychosom 2000; 69: 205-15. (Pubitemid 30413214)
9. Abbass A, Kisely S, Kroenke K. Short-term psychodynamic psychotherapy for somatic disorders: systematic review and meta-analysis of clinical trials. Psychother Psychosom 2009; 78: 265-74.
10. Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med 2007; 69: 881-8. (Pubitemid 350158831)
11. Hardy G, Barkham M, Shapiro D, Guthrie E, Margison F (eds). Psychodynamic- Interpersonal Psychotherapy. Sage, 2011 (in press).
12. Kroenke K, Spitzer RL, deGruy FV, Hahn SR, Linzer M, Williams JB, et al. Multisomatoform disorder: an alternative to undifferentiated somatoform disorder for the somatizing patient in primary care. Arch Gen Psychiatry 1997; 54: 352-8. (Pubitemid 27171921)
13. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. JAMA 1999; 282: 1737-44. (Pubitemid 29533604)
14. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
15. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders. Biometrics Research, New York State Psychiatric Institute, 2002.
16. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
17. Seivewright H, Green J, Salkovskis P, Barrett B, Nur U, Tyrer P. Cognitive-behavioural therapy for health anxiety in a genitourinary medicine clinic: randomised controlled trial. Br J Psychiatry 2008; 193: 332-7.
18. Rudolf G, Henningsen P. Psychotherapeutic treatment of somatoform disorders [in German]. Z Psychosom Med Psychother 2003; 49: 3-19.
19. Guthrie E. Adaptation of the psychodynamic-interpersonal model to work with medically unexplained symptoms. In Psychodynamic-Interpersonal Psychotherapy (eds G Hardy, M Barkham, D Shapiro, E Guthrie, F Margison). Sage, 2011 (in press).
20. Henningsen P, Working Group PISO. Psychodynamic-interpersonal therapy for somatoform disorders (PISO) - a manualized short-term psychotherapy [in German]. In Practice of Psychodynamic Psychotherapy [in German] (eds M Beutel, S Doering, F Leichsenring, G Reich). Hogrefe, 2011 (in press).
21. Rief W, Henningsen P. Somatoform disorders [in German]. In Practice of Psychotherapy [in German] (eds W Senf, M Broda). Thieme, 2005.
22. Shapiro DA, Startup M. Measuring therapist adherence in exploratory psychotherapy. Psychother Res 1992; 2: 193-203.
23. Henningsen P, Hartkamp N, Loew T, Sack M, Scheidt C, Rudolf G. Somatoform Disorders. Guidelines and Source Book [in German]. Schattauer, 2002.
24. Riddle DL, Lee KT, Stratford PW. Use of SF-36 and SF-12 health status measures: a quantitative comparison for groups versus individual patients. Med Care 2001; 39: 867-78. (Pubitemid 33686383)
25. Wiebe S, Matijevic S, Eliasziw M, Derry PA. Clinically important change in quality of life in epilepsy. J Neurol Neurosurg Psychiatry 2002; 73: 116-20.
26. Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003; 124: 303-17. (Pubitemid 36169247)
27. Kleinstaeuber M, Witthoeft M, Hiller W. Efficacy of short-term psychotherapy for multiple medically unexplained physical symptoms: a meta-analysis. Clin Psychol Rev 2011; 31: 146-60.
28. Pilowsky I. Dimensions of hypochondriasis. Br J Psychiatry 1967; 113: 89-93.
29. Fink P, Ewald H, Jensen J, Sørensen L, Engberg M, Holm M, et al. Screening for somatization and hypochondriasis in primary care and neurological in-patients: a seven-item scale for hypochondriasis and somatization. J Psychosom Res 1999; 46: 261-73. (Pubitemid 29118388)
30. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-94. (Pubitemid 32322245)
31. Cohen J. Statistical Power Analysis for the Behavioral Sciences (2nd edn). Erlbaum, 1988.
32. Looper KJ, Kirmayer LJ. Behavioral medicine approaches to somatoform disorders. J Consult Clin Psychol 2002; 70: 810-27. (Pubitemid 34640745)
33. Fonagy P. Psychotherapy research: do we know what works for whom? Br J Psychiatry 2010; 197: 83-5.
34. Roland M, Torgerson DJ. What are pragmatic trials? BMJ 1998; 316: 285.
35. Dickinson WP, Dickinson LM, deGruy FV, Main DS, Candib LM, Rost K. A randomized clinical trial of a care. recommendation letter intervention for somatization in primary care. Ann Fam Med 2003; 1: 228-35.
36. Sumathipala A, Siribaddana S, Abeysingha MRN, De Silva P, Dewey M, Prince M, et al. Cognitive-behavioural therapy v. structured care for medically unexplained symptoms: randomised controlled trial. Br J Psychiatry 2008; 193: 51-9. (Pubitemid 351946808)
37. Sattel H, Kittner A, Henningsen P. A brief psychodynamic-interpersonal psychotherapy for patients with multisomatoform disorder (PISO) -one size fits all? Psychother Psych Med 2011; 61: 111.
38. Krause MS, Lutz W. What should be used for baselines against which to compare treatments' effectiveness? Psychother Res 2009; 19: 358-67.
39. Morriss R, Dowrick C, Salmon P, Peters S, Dunn G, Rogers A, et al. Cluster randomised controlled trial of training practices in reattribution for medically unexplained symptoms. Br J Psychiatry 2007; 191: 536-42. (Pubitemid 350273215)
40. Guthrie E, Moorey J, Margison F, Barker H, Palmer S, McGrath G, et al. Cost-effectiveness of brief psychodynamic-interpersonal therapy in high utilizers of psychiatric services. Arch Gen Psychiatry 1999; 56: 519-26. (Pubitemid 29304645)